The results of this study are particularly relevant because the subjects examined essentially represent almost all patients with T2D and not just those with a history of cardiovascular disease, a preferential object in studies already conducted with other SGLT-2 inhibitors. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.